Pcsk9 proteins, fragments thereof and methods of modulating pcsk9 phosphorylation and low density lipoprotein (ldlr) degradation
AssigneeOttawa Health Research Institute
InventorsJanice Mayne, Michel Chretien, Majambu Mbikay
Life of this patent
Estimating the term…
Abstract
The present invention provide PCSK9 polypeptides, fragments thereof and methods of modulating PCSK9 phosphorylation and low density lipoprotein degradation.
Claims20
A PCSK9 polypeptide fragment comprising
- a) at least 7 consecutive amino acids of SEQ ID NO:1 or;
- b) an amino acid sequence that is at least 70% identical to the fragment defined in a).
A PCSK9 polypeptide comprising the amino acid sequence as defined by SEQ ID NO:1, wherein said polypeptide is phosphorylated at Serine 47, Serine 688 or both.
A PCSK9 polypeptide comprising one or more mutations, additions, deletions or a combination thereof in the amino acid sequence of SEQ ID NO:1.
A nucleotide sequence encoding the PCSK9 polypeptide as defined above.
A kit comprising,
- a) the PCSK9 polypeptide fragment thereof as defined above,
- b) the nucleic acid encoding the PCSK9 polypeptide fragment as defined above;
- c) the PCSK9 polypeptide defined above;
- d) the PCSK9 polypeptide defined above;
- e) the nucleic acid encoding the PCSK polypeptide as defined above;
- f) one or more pharmaceutically acceptable carriers, diluents, or excipients;
- g) one or more devices for delivering or administering one or more nucleic acids, PCSK polypeptides, fragments thereof or any combination thereof;
- h) instructions for administering one or more nucleic acids, PCSK polypeptides, fragments thereof or any combination thereof
- or
- i) any combination or sub-combination of a-h.
A method of modulating LDLR degradation comprising administering a compound that modulates LDLR degradation in a cell, cell culture or subject.
An antibody against a PCSK9 polypeptide or a fragment thereof.
Dependencies are inferred from the claim text.